Author: admin

DelveInsight’s “Chronic Venous Insufficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Venous Insufficiency, historical and forecasted epidemiology as well as the Chronic Venous Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Venous Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Venous Insufficiency Market Forecast

Some of the key facts of the Chronic Venous Insufficiency Market Report: 

• The Chronic Venous Insufficiency market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2022, Sky Medical Technology declared that it has obtained additional clearance from the US Food and Drug Administration (FDA) through the 510(k) pathway to introduce the latest (W3) geko device variant. This variant is designed to enhance microcirculatory blood flow within the lower limb soft tissue of individuals experiencing venous insufficiency.
• In 2022, the estimated total diagnosed prevalent cases of Varicose Ulcers in the Seven Major Markets (7MM) amounted to approximately 4,000,000. Among these cases, the United States recorded the highest prevalence of this disease.
• Within the Seven Major Markets (7MM), there was a higher prevalence of Varicose Ulcers observed in females compared to males.
• In the United States, the highest diagnosed prevalence of Varicose Ulcers was observed in individuals aged over 70 years, followed by the age group spanning from 60 to 70 years.
• In the EU4 countries, Germany recorded the highest count of diagnosed prevalent cases of Varicose Ulcers, followed by France. Conversely, Spain exhibited the lowest prevalent population affected by Varicose Ulcers.
• Key Chronic Venous Insufficiency Companies: Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and others
• Key Chronic Venous Insufficiency Therapies: P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and others
• The Chronic Venous Insufficiency epidemiology based on gender analyzed that Chronic Venous Insufficiency is more common in women than men.
• The Chronic Venous Insufficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Venous Insufficiency pipeline products will significantly revolutionize the Chronic Venous Insufficiency market dynamics.

Chronic Venous Insufficiency Overview

Chronic Venous Insufficiency (CVI) is a condition that occurs when the veins in the legs are unable to efficiently return blood to the heart. It often develops due to damaged or weakened valves in the veins, which normally help prevent blood from flowing backward. When these valves malfunction, blood can pool or flow backward (venous reflux), leading to various symptoms and complications.

Get a Free sample for the Chronic Venous Insufficiency Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/chronic-venous-insufficiency-market

Chronic Venous Insufficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Venous Insufficiency Epidemiology Segmentation:

The Chronic Venous Insufficiency market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Chronic Venous Insufficiency
• Prevalent Cases of Chronic Venous Insufficiency by severity
• Gender-specific Prevalence of Chronic Venous Insufficiency
• Diagnosed Cases of Episodic and Chronic Chronic Venous Insufficiency

Download the report to understand which factors are driving Chronic Venous Insufficiency epidemiology trends @ Chronic Venous Insufficiency Epidemiology Forecast

Chronic Venous Insufficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Venous Insufficiency market or expected to get launched during the study period. The analysis covers Chronic Venous Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Venous Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Venous Insufficiency Therapies and Key Companies

• P-TEV: Verigraft
• EscharEx: MediWound
• TTAX01: TissueTech/Amniox Medical
• Vessel: Alfasigma S.p.A
• Antistax®: Boehringer Ingelheim
• Coumarin/troxerutin: Takeda
• Venocur Triplex®: Abbott
• Detralex: Servier
• Esarin Gel: Ten Sun Pharma Company
• Sirolimus: Pfizer
• ticagrelor: AstraZeneca
• Neutrolin: JMI Laboratories

Discover more about therapies set to grab major Chronic Venous Insufficiency market share @ Chronic Venous Insufficiency Treatment Landscape

Scope of the Chronic Venous Insufficiency Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Venous Insufficiency Companies: Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and others
• Key Chronic Venous Insufficiency Therapies: P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and others
• Chronic Venous Insufficiency Therapeutic Assessment: Chronic Venous Insufficiency current marketed and Chronic Venous Insufficiency emerging therapies
• Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency market drivers and Chronic Venous Insufficiency market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Venous Insufficiency Unmet Needs, KOL’s views, Analyst’s views, Chronic Venous Insufficiency Market Access and Reimbursement 

To know more about Chronic Venous Insufficiency companies working in the treatment market, visit @ Chronic Venous Insufficiency Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Chronic Venous Insufficiency Market Report Introduction

2. Executive Summary for Chronic Venous Insufficiency

3. SWOT analysis of Chronic Venous Insufficiency

4. Chronic Venous Insufficiency Patient Share (%) Overview at a Glance

5. Chronic Venous Insufficiency Market Overview at a Glance

6. Chronic Venous Insufficiency Disease Background and Overview

7. Chronic Venous Insufficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Venous Insufficiency 

9. Chronic Venous Insufficiency Current Treatment and Medical Practices

10. Chronic Venous Insufficiency Unmet Needs

11. Chronic Venous Insufficiency Emerging Therapies

12. Chronic Venous Insufficiency Market Outlook

13. Country-Wise Chronic Venous Insufficiency Market Analysis (2019–2032)

14. Chronic Venous Insufficiency Market Access and Reimbursement of Therapies

15. Chronic Venous Insufficiency Market Drivers

16. Chronic Venous Insufficiency Market Barriers

17.  Chronic Venous Insufficiency Appendix

18. Chronic Venous Insufficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Venous Insufficiency Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Verigraft, MediWound, TissueTech/Amniox Medical

The Gene Therapies for Cardiomyopathies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gene Therapies for Cardiomyopathies Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gene Therapies for Cardiomyopathies Market.

Some of the key takeaways from the Gene Therapies for Cardiomyopathies Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gene Therapies for Cardiomyopathies treatment therapies with a considerable amount of success over the years. 
• Gene Therapies for Cardiomyopathies companies working in the treatment market are Lexeo Therapeutics, Biomarin, Solid Biosciences, Rocket Pharmaceuticals, Lexeo Therapeutics, and others, are developing therapies for the Gene Therapies for Cardiomyopathies treatment 

• Emerging Gene Therapies for Cardiomyopathies therapies in the different phases of clinical trials are- LX2021, BMN 293: MYBPC3 HCM, AVB-401, RP-A601, LX2006, and others are expected to have a significant impact on the Gene Therapies for Cardiomyopathies market in the coming years.   
• In July 2023, Novartis AG announced that the US Food and Drug Administration (FDA) has granted approval for a label revision for Leqvio® (inclisiran), permitting its earlier utilization as an adjunct to diet and statin therapy in individuals with elevated LDL-C levels at a heightened risk of heart disease1. This includes patients with conditions like hypertension and diabetes who haven’t encountered their initial cardiovascular event. Leqvio stands as the sole small interfering RNA (siRNA) medication endorsed by the FDA for reducing LDL-C levels, having received approval in December 2021.
• In April 2023, Bristol Myers Squibb has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of CAMZYOS® (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy (HCM) in adult patients categorized as New York Heart Association (NYHA) class II-III. The decision from the CHMP will now be evaluated by the European Commission (EC), which holds the authority to approve medicines for use within the European Union (EU).
• In August 2022, Lexeo Therapeutics has commenced a Phase I/II clinical trial, an open-label and escalating-dose study, aiming to assess both the safety and effectiveness of LX2006 in individuals diagnosed with Friedreich’s Ataxia coupled with indications of cardiomyopathy. This research will investigate the safety and potential efficacy of up to three doses of a single administration of LX2006 (AAVrh.10hFXN), a gene therapy utilizing an adeno-associated virus (AAV) designed to deliver the human frataxin (hFXN) gene intravenously to cardiac cells over a period of 52 weeks. Following the LX2006 treatment, an extended evaluation of safety and efficacy will be conducted for an additional 4-year period, culminating in a total assessment of 5 years post-treatment.

Gene Therapies for Cardiomyopathies Overview

Gene therapy for cardiomyopathies involves using genetic material to treat or manage various types of heart muscle diseases characterized by abnormal heart muscle structure or function. Cardiomyopathies are a group of conditions affecting the heart muscle, leading to inefficient pumping of blood, heart rhythm problems, or heart failure.

Get a Free Sample PDF Report to know more about Gene Therapies for Cardiomyopathies Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gene-therapies-for-cardiomyopathies-pipeline-insight

Emerging Gene Therapies for Cardiomyopathies Drugs Under Different Phases of Clinical Development Include:

• LX2021: Lexeo Therapeutics
• BMN 293: MYBPC3 HCM: Biomarin
• AVB-401: Solid Biosciences
• RP-A601: Rocket Pharmaceuticals
• LX2006: Lexeo Therapeutics

Gene Therapies for Cardiomyopathies Pipeline Therapeutics Assessment

• Gene Therapies for Cardiomyopathies Assessment by Product Type
• Gene Therapies for Cardiomyopathies By Stage and Product Type
• Gene Therapies for Cardiomyopathies Assessment by Route of Administration
• Gene Therapies for Cardiomyopathies By Stage and Route of Administration
• Gene Therapies for Cardiomyopathies Assessment by Molecule Type
• Gene Therapies for Cardiomyopathies by Stage and Molecule Type

DelveInsight’s Gene Therapies for Cardiomyopathies Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gene Therapies for Cardiomyopathies product details are provided in the report. Download the Gene Therapies for Cardiomyopathies pipeline report to learn more about the emerging Gene Therapies for Cardiomyopathies therapies

Some of the key companies in the Gene Therapies for Cardiomyopathies Therapeutics Market include:

Key companies developing therapies for Gene Therapies for Cardiomyopathies are – Novartis, Merck, Teva Pharma, Bristol Myers Squibb, Boston Scientific, Sanofi, Roche Holding, Astella Pharma, Critical Care Diagnostics, and others.

Gene Therapies for Cardiomyopathies Pipeline Analysis:

The Gene Therapies for Cardiomyopathies pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gene Therapies for Cardiomyopathies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gene Therapies for Cardiomyopathies Treatment.
• Gene Therapies for Cardiomyopathies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gene Therapies for Cardiomyopathies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gene Therapies for Cardiomyopathies market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gene Therapies for Cardiomyopathies drugs and therapies

Gene Therapies for Cardiomyopathies Pipeline Market Drivers

• Growing prevalence and incidence rates, increasing genetic research are some of the important factors that are fueling the Gene Therapies for Cardiomyopathies Market.

Gene Therapies for Cardiomyopathies Pipeline Market Barriers

• However, complex Pathophysiology, high Research Costs, limited Awareness and Diagnosis and other factors are creating obstacles in the Gene Therapies for Cardiomyopathies Market growth.

Scope of Gene Therapies for Cardiomyopathies Pipeline Drug Insight    

• Coverage: Global
• Key Gene Therapies for Cardiomyopathies Companies: Lexeo Therapeutics, Biomarin, Solid Biosciences, Rocket Pharmaceuticals, Lexeo Therapeutics, and others
• Key Gene Therapies for Cardiomyopathies Therapies: LX2021, BMN 293: MYBPC3 HCM, AVB-401, RP-A601, LX2006, and others
• Gene Therapies for Cardiomyopathies Therapeutic Assessment: Gene Therapies for Cardiomyopathies current marketed and Gene Therapies for Cardiomyopathies emerging therapies
• Gene Therapies for Cardiomyopathies Market Dynamics: Gene Therapies for Cardiomyopathies market drivers and Gene Therapies for Cardiomyopathies market barriers 

Request for Sample PDF Report for Gene Therapies for Cardiomyopathies Pipeline Assessment and clinical trials

Table of Contents

1. Gene Therapies for Cardiomyopathies Report Introduction

2. Gene Therapies for Cardiomyopathies Executive Summary

3. Gene Therapies for Cardiomyopathies Overview

4. Gene Therapies for Cardiomyopathies- Analytical Perspective In-depth Commercial Assessment

5. Gene Therapies for Cardiomyopathies Pipeline Therapeutics

6. Gene Therapies for Cardiomyopathies Late Stage Products (Phase II/III)

7. Gene Therapies for Cardiomyopathies Mid Stage Products (Phase II)

8. Gene Therapies for Cardiomyopathies Early Stage Products (Phase I)

9. Gene Therapies for Cardiomyopathies Preclinical Stage Products

10. Gene Therapies for Cardiomyopathies Therapeutics Assessment

11. Gene Therapies for Cardiomyopathies Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gene Therapies for Cardiomyopathies Key Companies

14. Gene Therapies for Cardiomyopathies Key Products

15. Gene Therapies for Cardiomyopathies Unmet Needs

16 . Gene Therapies for Cardiomyopathies Market Drivers and Barriers

17. Gene Therapies for Cardiomyopathies Future Perspectives and Conclusion

18. Gene Therapies for Cardiomyopathies Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Therapies for Cardiomyopathies Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis, Merck, Teva Pharma, Bristol Myers Squibb, Sanofi